Cantor Fitzgerald Investment Advisors L.P. Decreases Position in Organon & Co. (NYSE:OGN)

Cantor Fitzgerald Investment Advisors L.P. reduced its stake in Organon & Co. (NYSE:OGN - Free Report) by 35.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,183 shares of the company's stock after selling 44,315 shares during the period. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Organon & Co. were worth $1,179,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Millstone Evans Group LLC purchased a new position in shares of Organon & Co. in the 4th quarter valued at $29,000. Larson Financial Group LLC boosted its stake in Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after acquiring an additional 1,734 shares in the last quarter. Riverview Trust Co grew its holdings in shares of Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after purchasing an additional 1,292 shares during the last quarter. GeoWealth Management LLC purchased a new position in shares of Organon & Co. during the fourth quarter worth about $41,000. Finally, Jones Financial Companies Lllp increased its position in shares of Organon & Co. by 1,795.8% during the fourth quarter. Jones Financial Companies Lllp now owns 4,550 shares of the company's stock worth $68,000 after purchasing an additional 4,310 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Wall Street Analyst Weigh In

OGN has been the topic of a number of research reports. Morgan Stanley dropped their price target on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Piper Sandler reduced their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Organon & Co. presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Organon & Co. Trading Up 0.4%

NYSE:OGN opened at $9.89 on Friday. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $23.10. The company has a current ratio of 1.67, a quick ratio of 1.15 and a debt-to-equity ratio of 16.49. The stock's 50 day simple moving average is $9.91 and its 200-day simple moving average is $13.27. The firm has a market cap of $2.57 billion, a P/E ratio of 3.43, a PEG ratio of 1.03 and a beta of 0.58.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The company had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a net margin of 11.92% and a return on equity of 227.43%. Organon & Co.'s quarterly revenue was down 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.22 EPS. Equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Monday, May 12th were issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date was Monday, May 12th. Organon & Co.'s dividend payout ratio is presently 2.78%.

Insiders Place Their Bets

In related news, CFO Matthew M. Walsh bought 11,400 shares of the stock in a transaction on Monday, May 5th. The shares were bought at an average cost of $8.82 per share, for a total transaction of $100,548.00. Following the completion of the transaction, the chief financial officer now owns 144,484 shares of the company's stock, valued at $1,274,348.88. This represents a 8.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kirke Weaver purchased 8,045 shares of Organon & Co. stock in a transaction dated Tuesday, May 6th. The shares were bought at an average price of $9.21 per share, with a total value of $74,094.45. Following the completion of the transaction, the insider now owns 52,489 shares in the company, valued at approximately $483,423.69. This trade represents a 18.10% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 102,345 shares of company stock worth $902,430. Company insiders own 1.96% of the company's stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.